Katia Dyrda

Katia Dyrda

Auto-generated profile, based on publicly available information

Katia Dyrda

Montreal Heart Institute, Université de Montréal , 5000 Belanger St, Montreal, Quebec H1T 1C8

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2024 in EP Europace
Verified
Journal Article
Open access
STStylianos Tzeis
Stylianos Tzeis
EGEdward P Gerstenfeld
Edward P Gerstenfeld
JKJonathan Kalman
Jonathan Kalman
ESEduardo B Saad
Eduardo B Saad
Alireza Sepehri ShamlooAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
STSerge A Trines
Serge A Trines
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society .

8 April 2024 in Heart Rhythm
Verified
Journal Article
Open access
STStylianos Tzeis
Stylianos Tzeis
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld
JKJonathan Kalman
Jonathan Kalman
ESEduardo B. Saad
Eduardo B. Saad
Alireza Sepehri ShamlooAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
EWElaine Y. Wan
Elaine Y. Wan
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society.

13 April 2024 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
STStylianos Tzeis
Stylianos Tzeis
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld
JKJonathan Kalman
Jonathan Kalman
ESEduardo Saad
Eduardo Saad
Alireza Sepehri ShamlooAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
EWElaine Y. Wan
Elaine Y. Wan

6 October 2024 in Journal of Arrhythmia
Verified
Journal Article
Open access
STStylianos Tzeis
Stylianos Tzeis
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld
JKJonathan Kalman
Jonathan Kalman
ESEduardo B. Saad
Eduardo B. Saad
Alireza Sepehri ShamlooAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
EWElaine Y. Wan
Elaine Y. Wan
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence‐based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society

1 August 2022 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
DPDouglas L. Packer
Douglas L. Packer
DWDavid J. Wilber
David J. Wilber
SKSuraj Kapa
Suraj Kapa
KDKatia Dyrda
Katia Dyrda
INIsabelle Nault
Isabelle Nault
FIfor the SERF Investigators
for the SERF Investigators
Background: Ablation of ventricular tachycardia (VT) is limited by the inability to create penetrating lesions to reach intramyocardial origins. Intramural needle ablation using in-catheter, heated saline-enhanced radio frequency (SERF) energy uses convective heating to increase heat transfer and produce deeper, controllable lesions at intramural targets. This first-in-human trial was designed to evaluate the safety and efficacy of SERF needle ablation in patients with refractory VT. Methods: Thirty-two subjects from 6 centers underwent needle electrode ablation. Each had recurrent drug-refractory monomorphic VT after implantable cardioverter defibrillator implantation and prior standard ablation. During the SERF study procedure, one or more VTs were induced and mapped. The SERF needle catheter was used to create intramural lesions at targeted VT site(s). Acute procedural success was defined as noninducibility of the clinical VT after the procedure. Patients underwent follow-up at 30 days, and 3 and 6 months, with implantable cardioverter defibrillator interrogation at follow-up to determine VT recurrence. Results: These refractory VT patients (91% male, 66±10 years, ejection fraction 35±11%; 56% ischemic, and 44% nonischemic) had a median of 45 device therapies (shock/antitachycardia pacing) for VT in the 3 to 6 months pre-SERF ablation. The study catheter was used to deliver an average of 10±5 lesions per case, with an average of 430±295 seconds of radiofrequency time, 122±65 minute of catheter use time, and a procedural duration of 4.3±1.3 hours. Acute procedural success was 97% for eliminating the clinical VT. At average follow-up of 5 months (n=32), device therapies were reduced by 89%. Complications included 2 periprocedural deaths: an embolic mesenteric infarct and cardiogenic shock, 2 mild strokes, and a pericardial effusion treated with pericardiocentesis (n=1). Conclusions: Intramural heated saline needle ablation showed complete acute and satisfactory mid-term control of difficult VTs failing 1 to 5 prior ablations and drug therapy. Further study is warranted to define safety and longer-term efficacy. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03628534 and NCT02994446.

30 March 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
AVAtul Verma
Atul Verma
VEVidal Essebag
Vidal Essebag
PNPetr Neuzil
Petr Neuzil
KDKatia Dyrda
Katia Dyrda
JBJippe Balt
Jippe Balt
TPTom De Potter
Tom De Potter
The ultra-low-temperature cryoablation (ULTC) ablation system using −196°C N2 cryogen has been reported to create lesions with freeze duration–dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs). This prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1–9) to 0, IQR (0–2). In this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy. NCT04893317.